RGD Reference Report - Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats.

Authors: Suhara, Hitoshi  Sawa, Yoshiki  Fukushima, Norihide  Kagisaki, Koji  Yokoyama, Chieko  Tanabe, Tadashi  Ohtake, Shigeaki  Matsuda, Hikaru 
Citation: Suhara H, etal., J Thorac Cardiovasc Surg. 2002 May;123(5):855-61. doi: 10.1067/mtc.2002.118687.
RGD ID: 401959405
Pubmed: PMID:12019369   (View Abstract at PubMed)
DOI: DOI:10.1067/mtc.2002.118687   (Journal Full-text)


BACKGROUND: As one of the future strategies of advanced pulmonary hypertension, intrinsic prostacyclin drug delivery using gene therapy may be useful. We investigated whether transfer of the prostacyclin synthase gene into the liver could ameliorate monocrotaline-induced pulmonary hypertension in rats.
METHODS: The human prostacyclin synthase gene was transfected into the liver of rats with monocrotaline-induced pulmonary hypertension. Hemodynamic indices, blood samples, lung tissues, and survival curves were evaluated between rats receiving the gene and control rats.
RESULTS: High levels of prostacyclin synthase gene expression were found in the hepatocytes of the prostacyclin synthase group. The level of 6-keto-prostaglandin F(1alpha) was significantly higher in the prostacyclin synthase group (prostacyclin synthase, 35.4 +/- 4.4 ng/mL; control, 22.3 +/- 3.3 ng/mL; P =.0436). The right ventricular/femoral artery pressure ratio was significantly lower in the prostacyclin synthase group than in the control group (prostacyclin synthase, 0.60 +/- 0.039; control, 0.88 +/- 0.051; P =.0036). The endothelin-1 levels in the lung tissues were significantly lower in the prostacyclin synthase group than in the control group (prostacyclin synthase, 10.42 +/- 2.01 pg/mg protein; control, 19.94 +/- 2.82 pg/mg protein; P =.0176). The survival ratio was significantly higher in the prostacyclin synthase group than the control group (P =.0375).
CONCLUSION: This drug delivery system using gene transfer can be considered as an alternative for continuous intravenous prostacyclin infusion for pulmonary hypertension.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
PTGISHumanpulmonary hypertension treatmentIMP human gene in a rat modelRGD 
PtgisRatpulmonary hypertension treatmentISOPTGIS (Homo sapiens)human gene in a rat modelRGD 
PtgisMousepulmonary hypertension treatmentISOPTGIS (Homo sapiens)human gene in a rat modelRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ptgis  (prostaglandin I2 synthase)

Genes (Mus musculus)
Ptgis  (prostaglandin I2 (prostacyclin) synthase)

Genes (Homo sapiens)
PTGIS  (prostaglandin I2 synthase)


Additional Information